There is a clinical trial in progress to assess the safety and tolerability of recombinant human IL-22 IgG2-Fc (F-652) in combination with systemic corticosteroids for the treatment of acute gastrointestinal GVHD in hematopoietic stem cell transplantation recipients (ClinicalTrials.gov identifier NCT02406651; Generon Corporation Memorial and Sloan Kettering Cancer, 2016). The gene discussed is IL22; the disease is graft versus host disease.